{"entity":{"id":"nct05487170","kind":"trial","name":"A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)","aka":["CHAMP-1"],"tldr":"A phase 1/2 trial of RNK05047 in advanced solid tumours, run by Ranok Therapeutics (Hangzhou) Co., Ltd., now recruiting.","summary":"A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1) is a phase 1/2 interventional study registered as NCT05487170 by Ranok Therapeutics (Hangzhou) Co., Ltd., with 32 participants planned, started 2022-07-12 and due to reach its primary completion in 2025-06-01. Interventions recorded: RNK05047.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05487170","url":"https://clinicaltrials.gov/study/NCT05487170"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["rnk05047"],"companies":["ranok-therapeutics-hangzhou"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05487170","phase":"1/2","setting":"A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Chaperone-mediated Protein Degrader RNK05047 in Subjects With Advanced Solid Tumors (CHAMP-1)","sponsor":"Ranok Therapeutics (Hangzhou) Co., Ltd.","started":"2022-07-12","startedType":"actual","enrolled":32,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05487170/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"rnk05047","kind":"drug","name":"RNK05047","route":"/drugs/rnk05047/"}],"company":[{"id":"ranok-therapeutics-hangzhou","kind":"company","name":"Ranok Therapeutics (Hangzhou)","route":"/companies/ranok-therapeutics-hangzhou/"}]}}